drugset / Trial / NCT00088218

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

NCT00088218

RandomizedParallel-groupOpen-labelDiagnostic

Summary

The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in patients who are 60 years or older. The safety of these treatments will also be compared.

Timeline

Start
2004-07
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clofarabine Other / unclassified 30 mg/m2 Intravenous
Comparator Cytarabine Small molecule 20 mg/m2 Subcutaneous